
FY2023 JAX ANNUAL REPORT

OPERATING FINANCIALS BY YEAR



ENDOWMENT VALUE BY YEAR




OPERATING
REVENUE
FY2023

GENETIC RESOURCES
& CLINICAL RESEARCH
SERVICES

GOVERNMENT, FOUNDATION
AND OTHER GRANTS

OTHER





CONSOLIDATED BALANCE SHEETS

(in millions)

,	2023	2022
ASSETS		
Cash and Equivalents	\$ 17.1	21.3
Short-Term Investments, at Fair Value	217.4	241.6
Accounts Receivable, Net	67.0	68.0
Contributions Receivable, Net	27.6	3.6
Goodwill and Other Intangible Assets	47.6	48.9
Other Assets	54.6	49.1
Long-Term Investments, at Fair Value	410.4	376.2
Long-Lived Assets, Net	654.0	622.0
Total Assets	\$ <u>1,495.7</u>	1,430.7
LIABILITIES		
Accounts Payable and Accrued Expenses	\$ 121.9	93.0
Deposits and Deferred Revenue	15.4	14.9
Long-Term Debt, Net	359.8	368.6
Other Liabilities	15.2	13.7
Total Liabilities	512.3	490.2
Net Assets	983.4	940.5
Total Liabilities and Net Assets	\$ <u>1,495.7</u>	1,430.7

CONSOLIDATED STATEMENTS OF ACTIVITIES & CHANGES IN NET ASSETS

(in millions)

nillions)		2023	2022
OPERATING ACTIVITIES		2023	2022
Revenue and Other Support:	.	440.0	444 5
Government, Foundation and Other Grants	\$	112.2	111.7
Philanthropic Gifts Genetic Resources and Clinical Research Services		4.0 476.7	4.2 460.1
Investment Return		24.4	7.0
Other		2.7	0.7
Total Operating Revenue	_	620.0	583.7
Expenses:			
Research		169.5	160.6
Genetic Resources and Clinical Research Services		338.2	327.4
Training		11.4	10.2
Institutional Support	_	89.2	77.1
Total Operating Expenses	_	608.3	575.3
Change in Net Assets From Operating Activities	-	11.7	8.4
NON-OPERATING ACTIVITIES			
Grants and Contributions for Capital & Long-Term Investments		(1.1)	(3.1)
Long-Term Investment Return, Net of Amount Used		32.5	(72.6)
Increase (Decrease) in Net Assets from Non-Operating Activities	-	31.4	$\frac{(72.0)}{(75.7)}$
Other Changes in Net Assets	_	(0.1)	[29.6]
Total Increase (Decrease) Increase in Net Assets	\$_	43.0	[96.9]